Delivery Order SPE2DR25D3303-SPE2DR26F64H2
- Not listed
- The Defense Logistics Agency awarded a $8,745.36 firm fixed-price delivery order to AmerisourceBergen Drug Corp on December 1, 2025, for the supply of Zepbound 5 mg/0.5 ml pens. The contract, which has no set-aside designation, is scheduled for completion by December 2, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single transaction under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 1, 2025, for the supply of Zepbound 15 mg/0.5 mL pens with a ceiling value of $17,362.88. This is a firm fixed price delivery order with no set-aside designation, issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.9 million through December 2026. The product will be performed at AmerisourceBergen's facility in Conshohocken,...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $5,360.72 for Zepbound 7.5 mg/0.5 mL pens on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitive, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 18, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pens valued at $58,951.00, with completion by November 19, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $16,157.68 on December 18, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections. This non-competitive, firm fixed-price delivery order is set to be completed by December 19, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The award represents a single transaction under AmerisourceBergen's broader pharmaceutical supply relationship with the federal...
- The Defense Logistics Agency (DLA) awarded a $16,914.66 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pens on July 14, 2025, with completion targeted for July 15, 2025. This non-set-aside contract represents a single delivery order issued under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to the company's Conshohocken, Pennsylvania location, which...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 17, 2025, for the supply of Zepbound 2.5 mg/0.5 ml pen injections with a ceiling value of $1,632.17 and an ultimate completion date of December 18, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside contract and is being performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $8,973.55 to AmerisourceBergen Drug Corp on December 12, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pens. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was competitively made. The product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of December 15, 2025. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections, with a contract ceiling value of $15,472.34. This is a firm fixed-price delivery order with an ultimate completion date of July 29, 2025, and represents a non-competitive set-aside award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 11, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pens with a ceiling value of $2,755.80. This is a firm fixed-price delivery order with no set-aside designation, classified as a competitive award. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate completion date of December 12, 2025. This delivery order represents a child contract action...
- SPE2DR25D3303Indefinite Delivery Contract
- SPE2DR25D3303-SPE2DR26F64H2Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 22, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pens with a ceiling value of $1,607.30 and an ultimate completion date of December 23, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and running through December 2026. AmerisourceBergen Drug Corp serves as a major pharmaceutical distributor and critical federal medical procurement vendor, particularly supporting military and veteran healthcare systems through the DLA's Medical Supply Chain. This delivery order for Zepbound, a diabetes medication, exemplifies the company's role in supplying brand-name pharmaceuticals across multiple therapeutic domains to the Defense Health Agency and other government healthcare systems. The firm fixed-price structure and rapid completion timeline reflect the operational efficiency of AmerisourceBergen's established relationship with the DLA and its capability to fulfill federal medical supply requirements through competitive procurement processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.6k | 12/21/25 |